46. Malignant rheumatoid arthritis Clinical trials / Disease details
Clinical trials : 4,325 / Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2100048699 | 2021-05-25 | 2021-07-12 | A multicentre, randomized, parallel-controlled clinical study of the efficacy and safety of Iguratimod combination therapy with JAK inhibitor in the treatment of csDMARDs-IR active rheumatoid arthritis | Clinical cohort study of organ injury and repair in severe rheumatic diseases---rheumatoid arthritis | Rheumatoid Arthritis | A:Iguratimod combination therapy with JAK inhibitor;B:JAK inhibitor; | Qilu Hospital of Shandong University | NULL | Recruiting | 18 | 65 | Both | A:180;B:180; | China | |
| 2 | NCT04928066 (ClinicalTrials.gov) | March 1, 2020 | 9/6/2021 | The Efficacy and Safety of Tofacitinib (TF) With Iguratimod (IGU) on RA | Efficacy and Safety of Tofacitinib (TF) Combined With Iguratimod(IGU) in the Treatment of Moderate to Severe Active Rheumatoid Arthritis (RA) | Arthritis, Rheumatoid | Drug: Iguratimod;Drug: Tofacitinib;Drug: Pred | Qilu Hospital of Shandong University | NULL | Recruiting | 18 Years | 80 Years | All | 100 | Phase 4 | China |
| 3 | ChiCTR1900021686 | 2019-03-15 | 2019-03-05 | A observational study for iguratimod combined with methotrexate in remission or reversion bone erosion of rheumatoid arthritis | A observational study for iguratimod combined with methotrexate in remission or reversion bone erosion of rheumatoid arthritis | Rheumatoid arthritis | Case Series:IGU combined with MTX ; | Nanjing Drum Tower Hospital | NULL | Pending | 18 | 70 | Both | Case Series:30; | Phase 4 | China |
| 4 | ChiCTR1800015615 | 2018-05-01 | 2018-04-11 | Clinical observation of the protective effect of iguratimod on rheumatoid arthritis | Clinical observation of the protective effect of iguratimod on rheumatoid arthritis | Rheumatoid Arthritis | first:MTX;second:MTX in combination with Irammod;third:MTX and LEF;fourth:MTX, LEF and Irammod; | Tianjin First Central Hospital | NULL | Pending | 18 | 75 | Both | first:30;second:30;third:30;fourth:30; | China | |
| 5 | JPRN-UMIN000027719 | 2017/06/12 | 12/06/2017 | Effect of tapering methotrexate in rheumatoid arthritis patients after add-on iguratimod therapy. | rheumatoid arthritis/remission | add-on iguratimod tapering MTX continuing the treatment | Osaka Medical College | NULL | Recruiting | 20years-old | 100years-old | Male and Female | 100 | Not selected | Japan | |
| 6 | NCT03855007 (ClinicalTrials.gov) | January 1, 2017 | 15/2/2019 | The Clinical Efficacy and Safety of Iguratimod in RA and Early RA Patients for 6 Months Treatment | Prospective Clinical Study to Observe the Efficacy and Safety of Iguratimod in Rheumatoid Arthritis and Early Rheumatoid Arthritis Patients for 6 Months Treatment in China | Arthritis, Rheumatoid | Drug: Iguratimod;Drug: MTX;Drug: HCQ;Drug: Pred | Qilu Hospital of Shandong University | NULL | Active, not recruiting | 16 Years | 90 Years | All | 200 | Phase 4 | China |
| 7 | JPRN-UMIN000020833 | 2015/10/09 | 01/02/2016 | The efficacy of Iguratimod, and adding Adalimumab in patients with active rheumatoid arthritis: an open label multicenter randomized parallel study. | Rheumatoid arthritis | Administer MTX 6-16mg/week for 12 weeks to patients with MDA-RA. If patients can't take MTX, administer IGU 25-50mg/day or Tac 1.5-3.0mg/day for 12 weeks. Administer ADA 40mg/2weeks for 24weeks additionally, in case of MDA taking MTX or IGU, Tac for 12 weeks. If patients maintain remission for 24weeks, discontinue ADA by their own will, after 48 weeks administering ADA. | Zenjinkai Shimin-no-mori Hospital | NULL | Complete: follow-up complete | 20years-old | Not applicable | Male and Female | 240 | Not selected | Japan | |
| 8 | NCT02275299 (ClinicalTrials.gov) | September 2013 | 23/10/2014 | Study of Iguratimod Plus Methotrexate Compared to Leflunomid Plus Methotrexate in Patients With Rheumatoid Arthritis | A Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Iguratimod or Leflunomide in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis | Rheumatoid Arthritis | Drug: Iguratimod;Drug: Leflunomide;Drug: Methotrexate | Jiangsu Simcere Pharmaceutical Co., Ltd. | NULL | Recruiting | 18 Years | 70 Years | Both | 240 | Phase 4 | China |
| 9 | JPRN-JapicCTI-152782 | 12/9/2012 | 29/01/2015 | Investigation of the clinical safety and efficacy of iguratimod in patients with rheumatoid arthritis | Investigation of the clinical safety and efficacy of iguratimod in patients with rheumatoid arthritis | Rheumatoid Arthritis | Intervention name : Kolbet INN of the intervention : Iguratimod Dosage And administration of the intervention : Oral | Toyama Chemical Co., Ltd. (Current FUJIFILM Toyama Chemical Co., Ltd.) | NULL | BOTH | 2000 | NA | NULL | |||
| 10 | JPRN-JapicCTI-132051 | 12/9/2012 | 23/01/2013 | Investigation of the clinical safety and efficacy of iguratimod in patients with rheumatoid arthritis | Investigation of the clinical safety and efficacy of iguratimod in patients with rheumatoid arthritis | Rheumatoid Arthritis | Intervention name : iguratimod (Careram) Dosage And administration of the intervention : Oral | Eisai Co., Ltd. | NULL | BOTH | 2000 | NA | NULL | |||
| 11 | NCT01850966 (ClinicalTrials.gov) | September 12, 2012 | 8/5/2013 | Investigation of the Safety and Efficacy of Iguratimod in Patients With Rheumatoid Arthritis | Investigation of the Safety and Efficacy of Iguratimod in Patients With Rheumatoid Arthritis | Rheumatoid Arthritis | Drug: Iguratimod | Eisai Co., Ltd. | NULL | Completed | N/A | N/A | All | 2747 | Japan | |
| 12 | NCT01893151 (ClinicalTrials.gov) | July 2012 | 2/7/2013 | Effectiveness of Iguratimod Versus Placebo to Treat Early Rheumatoid Arthritis on MRI | A Randomized, Double-blind Study to Evaluate the Efficacy of Iguratimod Versus Placebo in Patients With Rheumatoid Arthritis on Magnetic Resonance Imaging (MRI) | Rheumatoid Arthritis | Drug: Iguratimod;Drug: Iguratimod placebo | Jiangsu Simcere Pharmaceutical Co., Ltd. | NULL | Recruiting | 18 Years | 65 Years | Both | 200 | Phase 4 | China |
| 13 | NCT01548001 (ClinicalTrials.gov) | May 2012 | 5/3/2012 | Long-term Efficacy of Iguratimod Alone or Iguratimod in Combination With Methotrexate in Patients With Rheumatoid Arthritis | A Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Iguratimod Alone or Iguratimod in Combination With Methotrexate Versus Methotrexate Alone in Patients With Rheumatoid Arthritis | Rheumatoid Arthritis | Drug: Iguratimod;Drug: Methotrexate | Jiangsu Simcere Pharmaceutical Co., Ltd. | NULL | Active, not recruiting | 18 Years | 65 Years | Both | 910 | Phase 4 | China |
| 14 | NCT01554917 (ClinicalTrials.gov) | May 2012 | 12/3/2012 | A Study of Iguratimod in Patients With Active Rheumatoid Arthritis | A Phase IV Study of Iguratimod in Patients With Active Rheumatoid Arthritis (RA) | Rheumatoid Arthritis | Drug: Iguratimod | Jiangsu Simcere Pharmaceutical Co., Ltd. | NULL | Completed | 18 Years | N/A | All | 1759 | Phase 4 | China |
| 15 | ChiCTR-TRC-10000850 | 2008-10-01 | 2010-04-26 | Phase III clinical trial of Iguratimodin rheumatoid arthritis | Phase III clinical trial of Iguratimodin rheumatoid arthritis | rheumatoid arthritis | 3:Experimental group: Iguratimod tablet, nimesulide dummy tablet; positive control group: taking nimesulide and Iguratimod dummy tablet; placebo group: taking Iguratimod dummy tablet and nimesulide dummy tablet. ; | Anhui Medical University | NULL | Completed | 18 | 65 | Both | 3:600; | 3 (Phase 3 study) | China |